Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

The drama continued Monday with senior FDA leaders as more details emerged about former Center for Drug Evaluation and ...

Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...

Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...